Zohydro v. Massachusetts = Wyeth v. Levine? State Asserts Power To Seek Label Change
This article was originally published in The Pink Sheet Daily
Arguing for its right to ban Zogenix Inc.’s opioid, Massachusetts contends that FDA clearance of a drug for marketing is a “gateway approval” that does not preempt states from imposing stricter requirements on a product.
You may also be interested in...
Zohydro Court Win: Deep Splash, But Few Ripples
Declaring that FDA product approval cannot be voided by Massachusetts, federal judge erases what could have been a strong challenge to agency authority; ruling is unlikely to change other state/federal dynamics, however.
Supreme Court’s Wyeth v. Levine Ruling Returns Industry To Status Quo On Pre-Emption
The court finds that FDA-approved labeling does not pre-empt individuals from bringing product liability suits under state law.
False Claims Act Liability: Defendant’s Belief Claims Were False Matters, Supreme Court Finds
In unanimous decision, court backs whistleblowers’ fraud theory that SuperValu and Safeway defrauded Medicare and Medicaid by reporting higher retail prices than their discounted prices. BIO, AdvaMed and MIWG submitted amicus brief in support of the retail pharmacies.